- The ethics of phase 0 oncology trials
[作者：Abdoler, E; Taylor, H; Wendler, D,期刊：Clinical Cancer Research, 页码：3692-3697 , 文章类型： Article，,卷期：2008年14-12]
- Recent guidance from the Food and Drug Administration supports the conduct of a new type of exploratory clinical trial, commonly called phase 0 clinical trials. Proponents argue that phase 0 clinical trials have the pote...
- T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease
[作者：Bergmann, C; Strauss, L; Wang, Y; Szczepanski, MJ; Lang, S; Johnson, JT; Whiteside, TL,期刊：Clinical Cancer Research, 页码：3706-3715 , 文章类型： Article，,卷期：2008年14-12]
- Purpose: Regulatory T cells play a major role in tumor escape from immunosurveillance. T regulatory cells type 1 (Tr1), a subset of regulatory T cells present in the tumor and peripheral circulation of patients with head...
- CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells
[作者：Li, WJ; Ge, Z; Liu, C; Liu, ZF; Bjorkholm, M; Jia, JH; Xu, DW,期刊：Clinical Cancer Research, 页码：3722-3728 , 文章类型： Article，,卷期：2008年14-12]
- Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor stabilizing c-MYC protein and driving cellular transformation. We determine whether CIP2A expression can serve as marker for gastric c...
- ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer
[作者：Liu, JW; Nagpal, JK; Sun, W; Lee, J; Kim, MS; Ostrow, KL; Zhou, S; Jeronimo, C; Henrique, R; Van Criekinge, W; Moon, CS; Califano, JA; Trink, B; Sidransky, D,期刊：Clinical Cancer Research, 页码：3754-3760 , 文章类型： Article，,卷期：2008年14-12]
- Purpose: Prostate cancer is a major cause of cancer death among men and the development of new biomarkers is important to augment current detection approaches.Experimental Design: We identified hypermethylation of the ss...
- Designing phase 0 cancer clinical trials
[作者：Murgo, AJ; Kummar, S; Rubinstein, L; Gutierrez, M; Collins, J; Kinders, R; Parchment, RE; Ji, J; Steinberg, SM; Yang, SX; Hollingshead, M; Chen, A; Helman, L; Wiltrout, R; Tomaszewski, JE; Doroshow, JH,期刊：Clinical Cancer Research, 页码：3675-3682 , 文章类型： Article，,卷期：2008年14-12]
- Phase 0 trials are designed primarily to evaluate the pharmacodynamic and/or pharmacokinetic properties of selected investigational agents before initiating more traditional phase I testing. One of the major objectives o...
- Phase 0 trials: An industry perspective
[作者：Eliopoulos, H; Giranda, V; Carr, R; Tiehen, R; Leahy, T; Gordon, G,期刊：Clinical Cancer Research, 页码：3683-3688 , 文章类型： Article，,卷期：2008年14-12]
- Worldwide, cancer is a leading cause of morbidity and mortality. An increased understanding of the disease and its process has resulted in a multitude of new targeted therapies. The costs as well as time from drug discov...
- Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers
[作者：Jeong, EG; Kim, MS; Nam, HK; Min, CK; Lee, S; Chung, YJ; Yoo, NJ; Lee, SH,期刊：Clinical Cancer Research, 页码：3716-3721 , 文章类型： Article，,卷期：2008年14-12]
- Purpose: The aim of this study was to see whether JAK1, JAK3, and TYK2 genes are altered in human cancers.Experimental Design: We analyzed 494 tissues from 186 acute adulthood leukemias, 30 multiple myelomas, and 278 com...
- Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
[作者：Lin, SH; Lee, YC; Choueiri, MB; Wen, SJ; Mathew, P; Ye, XC; Do, KA; Navone, NM; Kim, JR; Tu, SM; Yu-Lee, LY; Logothetis, CJ,期刊：Clinical Cancer Research, 页码：3729-3736 , 文章类型： Article，,卷期：2008年14-12]
- Purpose: Prostate cancer tends to metastasize to bone and induce osteoblastic lesions. We identified a soluble form of ErbB3 (sErbB3), p45-sErbB3, in bone marrow supernatant from men with prostate cancer bone metastasis ...
|